Francesco Maura, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Multiple myeloma
My Specialties
- Hematology
Get to Know Me
I am a hematologist who specializes in treating people with multiple myeloma and other plasma cell disorders. This includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma, which are both conditions that can turn into multiple myeloma.
I primarily see patients with multiple myeloma. I also see people in whom the myeloma has returned, as well as those for whom the cancer does not respond to standard treatments. For these patients, we consider salvage therapies and novel immunotherapies, a type of cancer treatment that uses the patient’s immune system to fight cancer.
At Memorial Sloan Kettering Cancer Center (MSK), our myeloma team provides highly specialized and innovative care for patients with multiple myeloma. Patients have access to the latest treatments as well as a vast portfolio of novel therapies.
Providing care is built on empathy and communication. I make sure patients understand their diagnosis and treatment path and answer their questions clearly. Beyond the treatment plan, my top priority is to establish a strong, communicative relationship with each patient, making sure they feel confident in their care.
I dedicate more than half of my time to research in my lab, where we analyze single-cell and bulk whole genome and RNA sequencing data from B-cell tumors, including multiple myeloma. My mission is to execute research that informs and helps advance clinical practices in cancer care.
Over the past few years, my lab has focused on modeling and integrating clinical and genomic data to better understand how multiple myeloma and other blood disorders such as lymphomas myeloid neoplasms, originate and develop. My goal is to develop genomics-based strategies to improve patient outcomes, prevent organ damage, and minimize side effects of treatments.
Outside of work, I enjoy spending time with my three boys.
I'm a hematologist (HEE-muh-TAH-loh-jist), which is a doctor with special training in blood disorders.
- Assistant Member
Conditions I Treat
- Multiple myeloma
My Specialties
- Hematology
Education
- MD, University of Milan, Italy
Residencies
- Hematology, University of Milan, Italy
Fellowships
- Onco-Hematology and Genomics, University of Milan, Italy
Awards and Honors
- Best Researcher of the Year, Sylvester Comprehensive Cancer Center, University of Miami Health System(2022)
- ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology (2021)
- OncLive Innovation Challenge Silver Award, OncLive (2019)
- International Myeloma Workshop Young Investigator Award, International Myeloma Society (2019)
- Societa’ Italiana Ematologia Abstract Achievement Award, American Society of Hematology (2018)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Maura F*, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O.J. Genomic Classification and Individualized Prognosis in Multiple Myeloma. Clin Oncol. 2024 Jan 9:JCO2301277. doi: 10.1200/JCO.23.01277. PMID: 38194610.
Maura F*, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9.PMID: 37945755.
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Bärtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F*. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma. Blood. 2024;144(7):771-783. doi: 10.1182/blood.2024024299.PMID: 38728430.
Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, Landgren O, Walter W, Meggendorfer M, Haferlach C, Haferlach T, Einsele H, Kortüm MK, Knop S, Alberge JB, Rosenwald A, Keats JJ, Rasche L, Maura F*, Neri P, Bahlis NJ. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31.PMID: 37653344.
Diamond B, Ziccheddu B, Maclachlan K, Taylor J, Boyle E, Ossa JA, Jahn J, Affer M, Totiger TM, Coffey D, Chandhok N, Watts J, Cimmino L, Lu SX, Bolli N, Bolton K, Landau H, Park JH, Ganesh K, McPherson A, Sekeres MA, Lesokhin A, Chung DJ, Zhang Y, Ho C, Roshal M, Tyner J, Nimer S, Papaemmanuil E, Usmani S, Morgan G, Landgren O, Maura F*. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023 May 11;141(19):2359-2371. doi: 10.1182/blood.2022018244.PMID: 36626250.
Visit PubMed for a full listing of Dr. Maura’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Francesco Maura discloses the following relationships and financial interests:
-
Mayo Clinic
Professional Services and Activities -
Medidata Solutions
Professional Services and Activities
-
Sanofi S.A.
Professional Services and Activities -
VJHemOnc
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.